Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Daily Rimegepant for Episodic Migraine Prevention
NCT05207865Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rimegepant in episodic migraine, sponsored by Pfizer. Started Mar 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05207865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207865.